Synbio Tech (ROCO:1295) Marketable Securities: NT$182 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:1295 Synbio Tech Inc ROCO:1295
42 GF Score
Price NT$46.70
! 9 Warning Signs
View Full Analysis

What is Synbio Tech Marketable Securities?

Synbio Tech ROCO:1295 +0.65% 42 Marketable Securities is NT$182 Mil as of Mar. 2026. GuruFocus rates ROCO:1295 with a GF Score™ of 42/100. The stock has 9 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Synbio Tech's Marketable Securities for the quarter that ended in Mar. 2026 was NT$182 Mil.

Synbio Tech's annual Marketable Securities stayed the same from Dec. 2023 (NT$0 Mil) to Dec. 2024 (NT$0 Mil) but then increased from Dec. 2024 (NT$0 Mil) to Dec. 2025 (NT$106 Mil).

Synbio Tech  (ROCO:1295) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Synbio Tech Marketable Securities Related Terms

Synbio Tech Marketable Securities Historical Data

* Premium members only.

The historical data trend for Synbio Tech's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synbio Tech Marketable Securities Chart

Synbio Tech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 208.84 190.18 0.00 0.00 106.29

Synbio Tech Quarterly Data
Dec20 Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 71.16 100.02 106.29 181.56
ROCO:1295
42GF Score
Synbio Tech Inc ROCO:1295
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Synbio Tech Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of NT$182 Mil mean?
Synbio Tech (ROCO:1295) has a Marketable Securities of NT$182 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Synbio Tech and its competitors.
Is Synbio Tech's Marketable Securities too high?
Synbio Tech's current Marketable Securities is NT$182 Mil. Overall, Synbio Tech has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Synbio Tech's Marketable Securities compare to VRTX and REGN?
Synbio Tech's Marketable Securities of NT$182 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Synbio Tech and its competitors. Synbio Tech's current Marketable Securities is NT$182 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synbio Tech stock overvalued right now?
Synbio Tech (ROCO:1295) has a current Marketable Securities of NT$182 Mil. The current Marketable Securities is NT$182 Mil. Synbio Tech's overall GF Score™ is 42/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Synbio Tech (ROCO:1295), the current Marketable Securities is NT$182 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Synbio Tech Business Description

Address No.82, Beiling 6th Road, Luzhu District, Kaohsiung, TWN, 821
Synbio Tech Inc focus on functional research and manufacturing of probiotics for human health and economic animals. It has two reportable segments, Taiwan and Mainland China Segment to engage in the production and R&D technologies of the Taiwan Segment, including the production and sales of concentrated fermentation liquid, lactobacillus plantarum solid drinks, and lactobacillus plantarum granules for animal husbandry. It generates majority of revenue from Taiwan segment includes production and sale of lactobacillus plantarum powder, lactobacillus plantarum fermentation derivative products, probiotics dietary supplements, probiotics products for pets and economic animals, and probiotics products. It has presence in Taiwan, China, Southeast Asia, and Others.
42GF Score

Get the complete analysis for ROCO:1295

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$46.70
Price